Phase I Trial of Intravenous Fenretinide (4-HPR) Plus Intravenous Safingol for Patients With Relapsed Malignancies
Phase of Trial: Phase I
Latest Information Update: 15 Dec 2017
At a glance
- Drugs Fenretinide (Primary) ; Safingol (Primary)
- Indications Non-Hodgkin's lymphoma; Solid tumours
- Focus Adverse reactions
- 16 Dec 2016 Planned primary completion date changed from 1 Mar 2014 to 1 Dec 2018.
- 16 Dec 2016 Status changed from not yet recruiting to recruiting.
- 21 Mar 2012 New trial record